Equity Profile

TECH

Bio-Techne Corporation

Health CareLife Sciences Tools & Services$8.1B

May6Wed

Post-Earnings Recap

ReportedQ3-2026Pre-Market6:30 AM EDT

Bio-Techne Corporation Misses Revenue, Stock Down 16.36%

Metric	Actual	Expected	Surprise
EPS	$0.53	$0.53	+11.11%
Revenue	—	$316M	—

management commentary, guidance changes, and full analysis available with Pro.

Bio-Techne Corporation Misses Revenue, Stock Down 16.36%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.53	$0.53	+11.11%
Revenue	—	$316M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

Bio-Techne Corporation reported earnings with EPS meeting expectations, but there was no revenue reported against the consensus of $316 million. The stock reacted negatively, dropping 16.36%, likely due to the lack of revenue information and guidance, which may raise concerns among investors about future performance.

Company Snapshot

Bio-Techne Corporation operates in the health care sector, focusing on life sciences tools and services. The company provides essential products for research and clinical applications, making it a key player in advancing scientific discovery and healthcare solutions.

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

0.53

Revenue

Revenue growth reflects the company's ability to expand its market presence and meet customer demand.

316M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q2-2026, Bio-Techne reported an EPS of $0.46, significantly exceeding expectations by 35.29%. The stock reacted positively, gaining 6.25% the following day.

Management Promises & Guidance

Continue to innovate in product development.
Expand market reach in key therapeutic areas.
Enhance customer support and service offerings.

Expectations

Wall Street Expectations

Analysts expect Bio-Techne to report solid earnings this quarter, with a consensus EPS of $0.53 and revenue of $316 million. The company has a strong track record of beating earnings estimates.

Bull Case

If Bio-Techne exceeds expectations, it could signal robust demand for its products and a strong market position, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet earnings expectations, it may raise concerns about growth sustainability and market competition, leading to a negative reaction in the stock.

Key Metrics to Watch

EPS

0.53

Earnings per share is a crucial indicator of the company's profitability and financial health.

Revenue

316M

Revenue growth reflects the company's ability to expand its market presence and meet customer demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.53?

A beat on EPS would reinforce investor confidence in the company's growth trajectory and ability to manage costs effectively.

What are the revenue expectations for key product lines?

Understanding revenue contributions from specific segments will help gauge market demand and competitive positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Bio-Techne's ability to capitalize on emerging market trends in life sciences, leading to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent product launches have shown promising early demand.

Historical performance indicates a consistent ability to exceed EPS estimates.

Options pricing suggests heightened volatility, indicating market anticipation of significant news.

Key Risk

If revenue from key product lines falls short of expectations, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Bio-Techne can maintain its momentum in a competitive market.

Bull Confirmed If

An EPS of $0.56 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.51 would raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±9.89%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±9.2% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

50.1%

Calls (10K)P/C Ratio: 0.59Puts (263K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 1.96%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around 1.96%, reflecting concerns about growth and market competitiveness.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue contributions from new product launches.
2Any updates on strategic partnerships or collaborations.
3Management's outlook on market trends and competitive dynamics.
4Insights into cost management and operational efficiencies.
5Guidance on future growth initiatives and investment plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a crucial indicator of the company's profitability and financial health.

0.53

Revenue

Revenue growth reflects the company's ability to expand its market presence and meet customer demand.

316M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q2-2026, Bio-Techne reported an EPS of $0.46, significantly exceeding expectations by 35.29%. The stock reacted positively, gaining 6.25% the following day.

Management Promises & Guidance

Continue to innovate in product development.
Expand market reach in key therapeutic areas.
Enhance customer support and service offerings.

Expectations

Wall Street Expectations

Analysts expect Bio-Techne to report solid earnings this quarter, with a consensus EPS of $0.53 and revenue of $316 million. The company has a strong track record of beating earnings estimates.

Bull Case

If Bio-Techne exceeds expectations, it could signal robust demand for its products and a strong market position, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet earnings expectations, it may raise concerns about growth sustainability and market competition, leading to a negative reaction in the stock.

Key Metrics to Watch

EPS

0.53

Earnings per share is a crucial indicator of the company's profitability and financial health.

Revenue

316M

Revenue growth reflects the company's ability to expand its market presence and meet customer demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.53?

A beat on EPS would reinforce investor confidence in the company's growth trajectory and ability to manage costs effectively.

What are the revenue expectations for key product lines?

Understanding revenue contributions from specific segments will help gauge market demand and competitive positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Bio-Techne's ability to capitalize on emerging market trends in life sciences, leading to stronger-than-expected revenue growth.

Supporting Evidence

The company's recent product launches have shown promising early demand.

Historical performance indicates a consistent ability to exceed EPS estimates.

Options pricing suggests heightened volatility, indicating market anticipation of significant news.

Key Risk

If revenue from key product lines falls short of expectations, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on whether Bio-Techne can maintain its momentum in a competitive market.

Bull Confirmed If

An EPS of $0.56 or higher would confirm strong operational performance and market demand.

Bear Confirmed If

An EPS below $0.51 would raise concerns about the company's growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±9.89%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings announcement.

Options are pricing ±9.2% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

50.1%

Calls (10K)P/C Ratio: 0.59Puts (263K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 1.96%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

A miss could lead to a decline of around 1.96%, reflecting concerns about growth and market competitiveness.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue contributions from new product launches.
2Any updates on strategic partnerships or collaborations.
3Management's outlook on market trends and competitive dynamics.
4Insights into cost management and operational efficiencies.
5Guidance on future growth initiatives and investment plans.